Get Involved

Haematology

Clinical research in haematology is improving treatment and services for people in the North East and North Cumbria

We are active in research across a number of areas of haematology care in both adults and children:

  • Thrombosis (blood clots) and anticoagulation: The group are working on improving the safety of existing anticoagulant (blood-thinning) treatments such as warfarin, and bringing new anticoagulants to many areas of clinical practice.
  • Haemophilia and bleeding disorders: Studies are focused on developing new treatments for haemophilia, an inherited disorder that often causes severe bleeding, and improving the quality of life for boys with this condition. Genetic studies are aiming to find out more about rarer bleeding disorders that affect platelet function.
  • Immune thrombocytopenia (ITP): This is an autoimmune condition that affects both children and adults. National registries are looking to find out more about the natural history of the disorder and which treatments are most successful.

There are haematologists active in research throughout the whole of the North East & North Cumbria region.

We are actively looking for people to join us in research activity across our region. Information about our team members and the studies in our region are available below.

Meet the Team

Tina Biss

Dr Tina Biss

Clinical lead and Consultant Haematologist at Newcastle Hospitals NHS Foundation Trust: Clinical lead, Dr Tina biss, 0191 2824743, tina.biss@nuth.nhs.uk;

Dr Rachel Wells

Clinical lead at Northumbria Healthcare NHS Foundation Trust: Dr Rachel Wells, rachel.wells@northumbria-healthcare.nhs.uk

Dr Scott Marshall

Clinical lead at City Hospitals Sunderland NHS Foundation Trust: scott.marshall3@nhs.net

Lynn Robson

Senior Research nurse at Newcastle Hospitals NHS Foundation Trust: Tel: 0191 2448767 email: lynne.robson@nuth.nhs.uk

Paula Newton

Senior research nurse at City Hospitals Sunderland NHS Foundation Trust email: paula.newton@chsft.nhs.uk

Dr Jamie Maddox

Clinical lead at South Tees Hospitals NHS Foundation Trust. email: jamie.maddox@stees.nhs.uk

Catherine Laven

Senior research nurse at South Tees Hospitals NHS Foundation Trust. Catherine Laven: email: catherine.laven@stees.nhs.uk

Catherine Ashbrook-Raby

Senior research nurse at Northumbria Healthcare Trust: Catherine.Ashbrook-Raby@northumbria-healthcare.nhs.uk Tel: 0191 2934094.

Clinical Trials in Haematology

Select a trial from the list below to find out more about what it’s all about and how you can get involved in helping others.

Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism

The study is for patients with cancer who have been on a blood-thinner for a new clot for less than 3 days (and fit other criteria).

UK Adult Idiopathic Thrombocytopenic Purpura (ITP) Registry

This is a registry study that is aiming to recruit hundreds of individuals with ITP within the UK.

UK Childhood ITP Registry

The main aims of this project are to try and understand why some children with a low platelet count bleed, when there is a need for treatment and how having ITP impacts on the quality of life on the child and family.

The United Kingdom Thrombotic Thrombocytopenic Purpura Registry (TTP Registry)

The information from this study may help us to increase our understanding and improve future treatment for patients with TTP.

The molecular investigation of unexplained anaemias and related congenital anaemias

The study is for patients who have anaemia for which no cause has been found.

Einstein Junior study (Phase II)

The aim is see if rivaroxaban is as good at treating and preventing recurrence of blood clots in children as standard treatment (warfarin or heparin). The study will also see if rivaroxaban causes less or more bleeding than standard treatment.

Einstein Junior study (Phase III)

Options for the treatment of thrombosis (blood clots) in children are limited. Anticoagulant (blood-thinning) therapy can either be with a tablet called warfarin which needs monitoring with regular blood tests, or a daily injection of heparin. Rivaroxaban is an anticoagulant that can be given as a tablet or syrup and does not need monitoring.

ECHO: Expanding Communications on Haemophilia-A Outcomes

A prospective, international, longitudinal, observational disease registry of patient-reported outcomes (PROs), and clinical impact of Haemophilia A and its treatment in patients with moderate to severe Haemophilia A.

UK-PK

This study will observe feelings when discussing PK guided dosing with patients in the clinic & the process of discussing their own, personal PK profile after a brief educational session.


Latest news from PPI

View all